Comparison of Mirabegron and Imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: a randomized controlled trial (COMFORT Study)

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2013
INTERVENTION: Mirabegron 50 mg is orally administered once daily for 12 weeks. Imidafenacin 0.1 mg is orally administered twice daily for 12 weeks. CONDITION: Overactive bladder PRIMARY OUTCOME: Change of total overactive bladder symptom score (OABSS) INCLUSION CRITERIA: 1)OAB patients (urgency score >= 2 and total score >= 3 in overactive bladder symptom score [OABSS]). 2)Twenty year‐old or more patients 3)Postmenopausal women 4)Patients from whom we received written informed consent
Epistemonikos ID: 50b42eb2e57e4f49dd7e528790f03161ce1cc8b6
First added on: Aug 22, 2024